HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-09-26Clinical Trial Update: A Pilot Gaming Adherence Program for Youth Living With HIV [NA]
A completed pilot trial evaluating a gaming adherence program for youth living with HIV, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-09-25Clinical Trial Update: Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial evaluating VM-1500 versus Efavirenz added to standard ART in HIV-1 infection has completed.
-
CLINICAL_TRIALS trial_result · 2018-09-25Clinical Trial Update: PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB [Phase 2]
Phase 2 trial updating pharmacokinetics of rifampicin interactions with Depo-Provera (DMPA) and efavirenz in HIV and TB patients; completed …
-
FDA approval · 2018-09-21FDA Approved: EFAVIRENZ — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's generic efavirenz (original ANDA) for the treatment of HIV-1 infection.
-
CLINICAL_TRIALS trial_result · 2018-09-19Clinical Trial Update: Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults [Phase 2]
A Phase 2 dose-finding study of BMS-955176 in treatment-naive adults with HIV-1 was terminated; results were posted in 2018.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients [Phase 3]
Phase 3 results update for an attachment inhibitor used in heavily treatment-experienced HIV-1 patients; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: Lactoferrin Treatment in HIV Patients [Phase 2]
Phase 2 clinical trial evaluating lactoferrin for HIV infection has completed and results have been posted.
-
FDA approval · 2018-09-17FDA Approved: RITONAVIR — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for Ritonavir, a generic protease inhibitor used in HIV therapy as a pharmacokinet…
-
FDA approval · 2018-09-17FDA Approved: RITONAVIR — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's Ritonavir original application (ANDA 206614), granting approval for a generic Ritonavir product.
-
FDA approval · 2018-09-17FDA Approved: RITONAVIR — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original ANDA for ritonavir, confirming a generic ritonavir product is eligible for marketing. Rit…
-
CLINICAL_TRIALS trial_result · 2018-09-14Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects [Phase 3]
A Phase 3 trial comparing a fixed-dose combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/…
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® [Phase 4]
Phase 4 trial update for EGRIFTA in HIV patients with diabetic retinopathy; study terminated.
-
FDA approval · 2018-09-10FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Retrovir (Zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2018-09-10FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for RETROVIR (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2018-09-10FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Retrovir (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2018-09-07FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for PREZISTA (darunavir) submitted by Janssen Products LP.
-
FDA approval · 2018-09-07FDA Approved: PREZCOBIX — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for PREZCOBIX (darunavir ethanolate and cobicistat) submitted by Janssen Products, LP.
-
FDA approval · 2018-09-06FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for JULUCA (dolutegravir and rilpivirine) from ViiV Healthcare, updating its label for HIV-1 tre…
-
FDA approval · 2018-09-06FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
FDA approves a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company.
-
FDA approval · 2018-09-06FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TIVICAY (dolutegravir) from ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2018-09-05Clinical Trial Update: Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults [Phase 4]
Phase 4 trial evaluating how HIV infection and active tuberculosis affect immune responses to the trivalent influenza vaccine in adults.
-
FDA approval · 2018-09-04FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Original Application (Aurobindo Pharma Limited)
FDA approved an original ANDA for a generic fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fuma…
-
CLINICAL_TRIALS trial_result · 2018-08-31Clinical Trial Update: Swiss HCVree Trial [Phase 3]
Phase 3 clinical trial completed for an intervention targeting Hepatitis C and HIV.
-
FDA approval · 2018-08-30FDA Approved: PIFELTRO — Original Application (Merck Sharp & Dohme LLC)
FDA approved PIFELTRO (doravirine) as an original approval for HIV-1 infection in adults and certain pediatric patients as part of combinati…
-
FDA approval · 2018-08-30FDA Approved: DELSTRIGO — Original Application (Merck Sharp & Dohme LLC)
The FDA approved Delstrigo, a fixed-dose combination tablet containing doravirine, lamivudine, and tenofovir disoproxil fumarate, as a compl…